Metformin vs. tirzepatide: which is better for weight loss?

If you've come across both metformin vs. tirzepatide in conversation about weight or blood sugar, you might be wondering how they compare and if one is better than the other. The direct answer is that tirzepatide produces far greater weight loss than metformin.

But that framing misses something important: These aren't two versions of the same medication, and they work through completely different mechanisms. For people with type 2 diabetes, the more relevant question is often whether they can be used together, not which one to choose.

This article covers how each medication works, what the weight loss data shows, and how to think about which option makes sense for your situation.

When it comes to tirzepatide vs. metformin for weight loss, tirzepatide is more effective by a wide margin. Clinical trials show people with obesity, or overweight (but without diabetes), lost an average of about 15%–21% of their body weight on tirzepatide.

Metformin is generally considered weight-neutral, meaning it’s not expected to cause significant weight gain or loss. Any weight reduction it produces is a secondary effect, not a primary outcome of the medication.

A meta-analysis of 49 randomized controlled trials found that metformin helped reduce body mass index (BMI) by 0.56 points compared to a placebo in adults with overweight or obesity without diabetes.

Comparing them for weight loss only makes sense in the context of type 2 diabetes, where both may be part of the same treatment plan.

Check for free

Clinical studies offer a clearer picture of how much weight loss to expect with each medication. Here’s what the research shows for tirzepatide and metformin.

Tirzepatide

The clearest picture of tirzepatide's weight loss potential comes from a SURMOUNT-1 trial, which enrolled adults with obesity or with overweight and at least one weight-related complication (except diabetes).

At 72 weeks, participants lost an average of 15% of their body weight on 5 mg of tirzepatide, 19.5% on 10 mg, and 20.9% on 15 mg. More than half of the participants on the two higher doses lost at least 20% of their body weight.

In people with type 2 diabetes, tirzepatide has also shown meaningful weight loss. A SURPASS-2 trial compared tirzepatide to semaglutide in patients already taking metformin, and found that tirzepatide led to greater reductions in HbA1c (a measure of average blood sugar levels) and body weight compared to semaglutide.

HbA1c decreased by 2.01%–2.30% with tirzepatide compared to 1.86% with semaglutide, and participants lost an additional 1.9–5.5 kg (~4.2 –12.1 pounds) more weight depending on the dose.

The safety profile of tirzepatide was consistent with that of the GLP-1 class of medications, with gastrointestinal side effects being the most common.

Metformin

Metformin isn’t considered a primary weight loss medication, but some studies suggest it may lead to modest, clinically meaningful weight reduction in certain groups.

The aforementioned meta-analysis of 49 trials found that metformin reduced BMI by about 0.56 points on average compared to placebo and by about 2.5% at doses around 1,700 mg per day.

A separate study of 222 adults with obesity found that participants lost an average of 6–7 kg (~6%–8% of their body weight) over 6–12 months on metformin alone. Results were similar in people with and without type 2 diabetes or prediabetes, suggesting the weight effects aren't limited to blood sugar status.

There’s also interest in how metformin works alongside newer medications. In conditions like polycystic ovary syndrome (PCOS), metformin is often used to improve insulin resistance, while GLP-1–based therapies have shown stronger effects on weight loss. 

Emerging research suggests these medications may have complementary roles, with combination approaches being explored to improve both metabolic and reproductive outcomes.

Metformin is an oral medication that received US Food and Drug Administration (FDA) approval in 1994. It is approved for controlling blood sugar levels in people with type 2 diabetes, alongside diet and exercise. It’s usually taken once or twice daily and is available as a low-cost generic as well as in several brand-name and combination products.

Metformin also has several common off-label uses, such as PCOS and prediabetes.  According to the American Diabetes Association, both metformin and lifestyle changes can help prevent or delay type 2 diabetes in people with prediabetes — but lifestyle changes have the strongest and longest-lasting effect.

Metformin isn’t approved by the FDA for weight loss. Any weight loss effects it produces are mild and secondary to its glucose-lowering action. The medication is widely available and supported by decades of safety data, making it key for type 2 diabetes management.

Long-term use may be associated with reduced vitamin B12 levels. Metformin carries a warning for lactic acidosis, a rare but serious condition. Risk factors include kidney or liver impairment, older age, surgery, low oxygen levels, and heavy alcohol use.

Tirzepatide is a once-weekly injectable medication that simultaneously activates two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

It’s the active ingredient in two FDA-approved products:

• Mounjaro, a weekly injection that can improve blood sugar control in people with type 2 diabetes.

• Zepbound, a weekly injection that can help reduce and manage chronic weight in adults with obesity or with overweight and at least one weight-related condition. It can also help treat obstructive sleep apnea in adults with obesity.

Tirzepatide has shown significant weight loss results in people with and without type 2 diabetes when used in addition to changes in diet and exercise.

Metformin and tirzepatide reduce blood sugar through completely different pathways, and their effects on weight follow from those differences.

Metformin reduces how much glucose the liver produces, decreases how much glucose is absorbed from food in the intestines, and improves how the body responds to insulin. Together, these effects help lower both fasting and post-meal blood sugar levels.

It’s considered weight-neutral, though some people may experience modest weight loss, and it’s unlikely to cause low blood sugar on its own. Metformin is processed by the kidneys rather than the liver, so kidney function needs to be monitored during treatment.

Tirzepatide works by activating the GIP and GLP-1 receptors in the brain, which helps reduce hunger and food cravings while increasing feelings of fullness. It slows digestion so food moves through more gradually, helping you feel satisfied for longer after eating. 

In the pancreas, it improves insulin production and lowers glucagon, a hormone that raises blood sugar. 

These combined effects on appetite and metabolism are the primary driver of tirzepatide’s significant weight loss outcomes.

The two drugs aren’t interchangeable. They target different pathways and produce different results.

Metformin and tirzepatide are sometimes used together for managing type 2 diabetes, though large-scale clinical trial data on the combination specifically for weight loss is limited.

In type 2 diabetes management, metformin is typically a first-line medication. If blood sugar targets aren’t met after three months on metformin alone, a healthcare provider may add a GLP-1 receptor agonist like tirzepatide, particularly for people who also need to lose weight.

In one case report, metformin was added to an existing tirzepatide regimen and was associated with further reductions in hunger and additional weight loss. Larger studies are needed to better characterize how the two medications work together.

Gastrointestinal side effects are a common issue with both medications individually. Your healthcare provider may recommend monitoring and dose adjustments if needed.

If you have questions about the safety of metformin vs. Mounjaro or Zepbound for weight loss, talk to your healthcare provider about which option is appropriate for your health history and goals.

Whether you're taking one or both of these medications, what you do alongside them matters. In fact, tirzepatide (as Zepbound) is approved alongside a reduced-calorie diet and increased physical activity. 

The American Diabetes Association also emphasizes lifestyle changes as a core part of long-term management of type 2 diabetes. Here are some habits that can help with diabetes management specifically:

• Eat protein and vegetables first: Eating protein and vegetables first, and waiting about 30 minutes before having carbohydrates, may help reduce blood sugar spikes after meals.

• Keep meals low-carbohydrate and balanced: Eating most of your carbohydrates earlier in the day rather than later may also support better glucose control.

• Move after meals: Moderate exercise in the window after eating can help reduce post-meal blood sugar spikes without causing low blood sugar.

• Be mindful with pre-meal exercise: Exercising before a meal may improve insulin sensitivity, but in some cases, it can raise blood sugar shortly after or lead to delayed low blood sugar later.

Both metformin and tirzepatide are generally well tolerated, but they come with different side effect profiles and safety considerations. Understanding these differences can help you know what to expect with each medication.

Metformin side effects

The most common side effects of metformin are gastrointestinal, including diarrhea, nausea, and vomiting, and may affect up to 30% of people who take it. Headache, chest discomfort, weakness, runny nose, or abnormal sweating are less common.

These effects are usually manageable, and metformin is generally well-tolerated and safe. 

Long-term use has been associated with reduced vitamin B12 levels, so your provider may monitor for this or suggest a B12 supplement, especially if you have anemia or peripheral neuropathy.

Metformin also carries a boxed warning for lactic acidosis, a rare but serious buildup of lactic acid in the blood. Symptoms may include fatigue, trouble breathing, and changes in blood pH, and it can become critical if not treated.

This risk is higher in people with kidney or liver issues, older adults, surgery, and those with low oxygen (hypoxia) or who drink alcohol heavily. People taking metformin are usually advised to limit alcohol intake.

Certain medications can interact with metformin. Some, such as bupropion, cimetidine, and iodinated contrast agents, may increase the risk of lactic acidosis. Others, including some antidepressants and antidiabetic agents, may enhance metformin's blood sugar-lowering effect, which can raise the risk of hypoglycemia.

So, it’s important to tell your healthcare provider about all medications you’re taking before starting metformin.

Tirzepatide side effects

The most common side effects of tirzepatide are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and acid reflux.

These effects are usually mild to moderate and tend to improve over time. Less commonly, tirzepatide may cause injection site reactions, increased heart rate, or dehydration, which in rare cases can lead to kidney issues.

There is also a risk of pancreatitis, and people are advised to seek immediate care if they experience severe abdominal pain. Gallbladder-related issues such as gallstones have also been reported.

Like other medications in this category, tirzepatide carries an FDA boxed warning about a possible risk of thyroid C-cell tumors, based on animal studies.

It isn’t known whether tirzepatide causes thyroid tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide isn’t recommended for anyone with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN 2).

For most people with type 2 diabetes, the conversation of metformin vs. tirzepatide isn’t necessarily an either-or situation. Metformin and tirzepatide can be used together, and both may play a role depending on your treatment goals and how your body responds.

If you don’t have diabetes and are looking to lose weight, tirzepatide (as Zepbound) is an appropriate option to discuss. Metformin isn’t approved for weight loss, and most evidence doesn’t support using it solely for that purpose. For people with conditions that may benefit from metformin, such as PCOS or prediabetes, its low cost can make it a worthwhile option.

For people with type 2 diabetes, metformin is usually the starting point because it is highly effective, low-cost, and easy to take. Tirzepatide may be added if blood sugar goals aren’t met with metformin alone.

Both medications are prescription drugs, so the right approach should be decided with a licensed healthcare provider who can evaluate your health history, goals, and tolerance.

If you're unsure which option is right for you, talk to a healthcare provider. This can be done in person or virtually, such as on Ro. 

Get started

When comparing metformin vs. tirzepatide, it’s important to know the basics: Both can be used in type 2 diabetes management, but they serve very different roles. Here's what else to keep in mind:

• Tirzepatide can produce significant weight loss (far more than metformin). In clinical trials, people with obesity or overweight lost an average of up to 20.9% of their body weight over 72 weeks on tirzepatide.

• Metformin isn’t a weight loss drug. Any weight reduction with metformin is modest and secondary. It’s a well-established, first-line treatment for controlling blood sugar levels in people with type 2 diabetes.

• They can be used together in some cases. In type 2 diabetes management, metformin is typically a first-line medication, and tirzepatide may be added if blood sugar targets aren't met. Your healthcare provider will determine the right combination and monitor you along the way.

• The right choice when considering metformin vs. tirzepatide depends on your situation. If you have type 2 diabetes, a healthcare provider can assess whether metformin, tirzepatide, or both make sense for your goals. If you’re seeking weight loss without diabetes, tirzepatide (Zepbound) is most often the appropriate option to discuss.

Treatment decisions should always be made with a licensed healthcare provider who can evaluate your full health history.